China Isotope & Radiation : VOLUNTARY ANNOUNCEMENT - ENTERING INTO THE STRATEGIC COOPERATION FRAMEWORK AGREEMENT WITH NUCLEAR INDUSTRY HOSPITAL

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHINA ISOTOPE & RADIATION CORPORATION

中 國 同 輻 股 份 有 限 公 司

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1763)

VOLUNTARY ANNOUNCEMENT

ENTERING INTO THE STRATEGIC COOPERATION FRAMEWORK AGREEMENT WITH NUCLEAR INDUSTRY HOSPITAL

This announcement is made by China Isotope & Radiation Corporation (the "Company" or "CIRC") on a voluntary basis to inform its shareholders and potential investors of its latest business development.

The board of directors (the "Board") of the Company is pleased to announce that, on 13 August 2020, the Company and Nuclear Industry Hospital entered into a strategic cooperation framework agreement.

Pursuant to the agreement, both parties would commence in-depth cooperation in terms of disciplines establishment, technology innovation, talents nurturing and international cooperation with an aim to accomplish mutual benefits and joint development by putting the advantages of both parties into full play. Leveraging on its advantages, CIRC will proactively participate in the construction of the "nuclide diagnostic center" and the "nuclear technology clinical research center" newly established by Nuclear Industry Hospital. Both parties will cooperate to make researches and breakthroughs in areas such as new nuclide diagnosis products and technologies as well as clinical application and conversion of nuclear technology, thereby jointly enhancing the overall level of nuclear technology application and nuclear medication in the PRC.

As a class III grade A hospital integrating the functions of medication, education, scientific researches, prevention and nuclear emergency response, Nuclear Industry Hospital is a State Clinical Trial Base, a State Hospitalist Standardised Training Base, a State Nuclear Emergency Medical Rescue Base, a State Stroke Center and a National Chest Pain Center. Nuclear Industry Hospital possesses a State Key Laboratory of Radiation Medicine and Protection, a Radiation Medicine and Conversion Center, 7 key laboratories at municipal level, 4 university clinical trial research institutes as well as a platform for domestic multi-center cooperation, while having extensive cooperation with France, the United States, Japan and Israel.

1

CIRC is a subsidiary of China National Nuclear Corporation specialising in nuclear technology application with business coverage including production of radioactive source, production of radioactive medicine, industrial nuclear applications, medical diagnosis, research and development/ services of nuclear medical devices, production of nuclides and import and export trading.

Through the cooperation, both parties join force and open access to the frontline and application industry chain of nuclear medication in terms of nuclear technology application. By establishing an integrated clinical platform, being a domestically top-notch and internationally renowned nuclear technology medication application foundation, it offers an essential support to the Company for nuclear technology application in terms of talents nurturing, technological innovation and industry development. Both parties could attain complementarities and innovation, while establish a center leading innovation and radiative development with considerable influence, and hence representing a new driving force for quality development of nuclear technology application industries.

Entering into the strategic cooperation framework agreement does not constitute a notifiable transaction under Chapter 14 and a connected transaction under Chapter 14A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board

China Isotope & Radiation Corporation

Meng Yanbin

Chairman

Beijing, the PRC, 14 August 2020

As at the date of this announcement, the Board comprises Mr. Meng Yanbin, Mr. Wu Jian and Mr. Du Jin as executive Directors; Mr. Zhou Liulai, Mr. Chen Shoulei, Mr. Chen Zongyu, and Ms. Chang Jinyu as non-executive Directors; Mr. Guo Qingliang, Mr. Meng Yan, Mr. Hui Wan Fai and Mr. Tian Jiahe as independent non-executive Directors.

2